Baxter Gains FDA Clearance for Bone Graft Substitute

Baxter International was granted FDA 510(k) clearance to market Actifuse Flow bone graft substitute, offered in a prepackaged delivery syringe for precise placement into small bony voids or gaps.

U.S. launch is expected by 4Q18, and Actifuse Flow will be sold in 1.5-, 3- and 5-mL sizes. The product has application in a variety of orthopaedic...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us